

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

26. (Currently amended) A monovalent influenza vaccine composition comprising an influenza virus component which is a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 μg of haemagglutinin per dose or no more than 15 μg per combined dose of vaccine and wherein the adjuvant is an aluminium salt or salts.

27. (Previously presented) A vaccine composition according to claim 26 wherein the influenza virus antigen is in the form of purified whole influenza virus.

28. (Cancelled).

29. (Currently amended) A vaccine composition according to claim [28] 26 wherein the adjuvant is aluminium hydroxide and aluminium phosphate.

30. (Previously presented) A vaccine composition according to claim 29 wherein the amount of aluminium phosphate exceeds the amount of aluminium hydroxide.

31. (Currently amended) A vaccine composition according to claim [28] 26 wherein the aluminium salts are present in the range 0.4 to 1.0 mg per vaccine dose.

32. (Currently amended) A vaccine composition according to claim [28] 26 in which the low antigen dose is less than 10 μg of haemagglutinin per dose or per combined dose of vaccine.

33. (Previously presented) A vaccine composition according to claim 32 in which the antigen dose is between 0.1 μg and 7.5 μg or between 1 and 5 μg of haemagglutinin per dose or per combined dose of vaccine.

34. (Currently amended) A vaccine composition according to claim [28] 26 wherein the influenza virus antigen is substantially free of host cell contamination.

35. (Currently amended) A vaccine composition according to claim [28] 26 wherein the influenza virus component is purified by a method which includes a protease incubation step to digest non-influenza virus proteins.

36-40. (Canceled).

41. (Currently amended) A method for the production of an influenza vaccine for a pandemic situation which method comprises admixing egg-derived influenza virus antigen from a single influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, with a suitable adjuvant, wherein the adjuvant is an aluminium salt or salts, and providing vaccines lots or vaccine kits which contain less than 10 µg influenza haemagglutinin antigen per dose or no more than 15 µg haemagglutinin per combined dose.

42. (Previously presented) A method according to claim 41 wherein the antigen is highly purified.

43. (Previously presented) A method according to claim 41 wherein the influenza virus antigen is in the form of whole influenza virus particles.

44. (Currently amended) The vaccine composition of claim [28] 26 wherein the antigen is selected from an H2 antigen such as H2N2 and an H5 antigen such as H5N1.

45. (Canceled).

46. (Previously presented) The method of claim 41 wherein the antigen is selected from an H2 antigen such as H2N2 and an H5 antigen such as H5N1.

47-50. (Canceled).